Artiva Biotherapeutics, Inc. 4

Director Alison Moore was granted a stock option for 13,750 shares of Artiva Biotherapeutics, Inc. common stock at an exercise price of $10.88 per share as director compensation.

On September 8, 2026, Director Alison Moore received a grant of a stock option to purchase 13,750 shares of Artiva Biotherapeutics, Inc. common stock at an exercise price of $10.88 per share. The option is a director compensation award that will vest in full on the earlier of September 8, 2027, or the date of the issuer's 2027 annual stockholder meeting, and will expire on September 7, 2036. The reported post-transaction direct ownership is 13,750 shares, reflecting this new option grant; based on the exercise price, the option grant represents an underlying equity value of approximately $149,600.

Filing Facts

CIK

1817241

Ticker

ARTV

Form

4

Source Type

fda

Accession

0001193125-26-385409

Alert Tier

5